Cross-Reactive Antibodies to SARS-CoV-2 and MERS-CoV in Pre-COVID-19 Blood Samples from Sierra Leoneans.

Rodrigo Borrega,Mambu Momoh,Lansana Kanneh,Jaikin E Harrell,Robert J Samuels,Zoe L Branco,Whitney N Phinney,Kristian G Andersen,John Demby Sandi,Luis M Branco,Megan L Heinrich,Kaylynn J Genemaras,Nell G Bond,Raju Lathigra,Matthew L Boisen,Andrew R Hoffmann,Pardis C Sabeti,Julie A Rouelle,Dahlene N Fusco,James E Robinson,Irina Aimukanova,Megan M Rowland,Jeffrey G Shaffer,Sophia A Koval,Augustine Goba,Michael Gbakie,Antoinette R Bell-Kareem,Duane J Bush,John S Schieffelin,Donald S Grant,Lilia I Melnik,Allison R Smither,Patricia Snarski,Karissa Chao,Robert F Garry,Alexandra Melton ,Debra Elliott ,Arnaud Drouin ,Anatoliy Koval ,Diana Nelson ,Gilberto Sabino‐Santos ,Ashley R Smira

doi:10.3390/v13112325

Abstract

Many countries in sub-Saharan Africa have experienced lower COVID-19 caseloads and fewer deaths than countries in other regions worldwide. Under-reporting of cases and a younger population could partly account for these differences, but pre-existing immunity to coronaviruses is another potential factor. Blood samples from Sierra Leonean Lassa fever and Ebola survivors and their contacts collected before the first reported COVID-19 cases were assessed using enzyme-linked immunosorbent assays for the presence of antibodies binding to proteins of coronaviruses that infect humans. Results were compared to COVID-19 subjects and healthy blood donors from the United States. Prior to the pandemic, Sierra Leoneans had more frequent exposures than Americans to coronaviruses with epitopes that cross-react with severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), SARS-CoV, and Middle Eastern respiratory syndrome coronavirus (MERS-CoV). The percentage of Sierra Leoneans with antibodies reacting to seasonal coronaviruses was also higher than for American blood donors. Serological responses to coronaviruses by Sierra Leoneans did not differ by age or sex. Approximately a quarter of Sierra Leonian pre-pandemic blood samples had neutralizing antibodies against SARS-CoV-2 pseudovirus, while about a third neutralized MERS-CoV pseudovirus. Prior exposures to coronaviruses that induce cross-protective immunity may contribute to reduced COVID-19 cases and deaths in Sierra Leone.

Highlights

A mystery surrounding the COVID-19 pandemic has been the relatively low case numbers and deaths in sub-Saharan Africa compared to other regions worldwide [1–4]
Pre-existing immunity to coronavirus antigens should be further investigated as a potential factor contributing to reduced caseloads and deaths from COVID-19 in Sierra Leone
Several studies have reported T cell reactivity against SARS-CoV-2 in people with no known exposure to the virus, which may in part be related to prior exposure to seasonal coronaviruses

Summary

Introduction

A mystery surrounding the COVID-19 pandemic has been the relatively low case numbers and deaths in sub-Saharan Africa compared to other regions worldwide [1–4]. While higher COVID-19 case numbers have been reported in North Africa and Southern Africa [5], several West African nations had experienced far fewer infections, with Sierra Leone, Mali, Benin, Burkina Faso, and Nigeria all with circa 100 confirmed cases per 100,000 people or less. This trend extends to several countries in Middle Africa, including the Democratic Republic of the Congo, Chad, and Niger. A major excess mortality beyond that expected for the region has not been observed between March 2020 and August 2021, arguing against large numbers of missed cases Another imperfect means of estimating COVID-19 caseloads is via serosurveys [3,6]. A recent study in Sierra Leone provided serological evidence that the number of SARS-CoV-2 infections is low relative to countries in Europe and the Americas [7]

Methods

Results

Conclusion